TIMM | Jotup

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on:

Thursday, March 28, 2024

“SCY-247 continues to demonstrate highly encouraging preclinical results, with potent activity against a broad range of fungal pathogens, including mucormycosis.

Key Points:

“SCY-247 continues to demonstrate highly encouraging preclinical results, with potent activity against a broad range of fungal pathogens, including mucormycosis.
In March 2023, SCYNEXIS and GSK entered into an exclusive license agreement for the development, manufacturing and commercialization of ibrexafungerp (BREXAFEMME).
Presented preclinical data on SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) held in Athens, Greece October 20-23, 2023.
Cash, cash equivalents and investments totaled $98.0 million on December 31, 2023, compared to $73.5 million on December 31, 2022.

Puma Exploration Reviews 2023 Accomplishments and Outlines Plans for 2024

Retrieved on:

Wednesday, January 17, 2024

Lynx, Artemis program, Development, Gold, Acquisition, Williams Brook, Knowledge, Outline, OTCQB, CCI, PUMA, Option, TIMM, News, Mining

RIMOUSKI, Quebec, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the "Company" or "Puma") is pleased to outline its key accomplishments and discoveries in 2023 and present its proposed 2024 Exploration Program at its 100% owned Williams Brook Gold Project located in Northern New Brunswick.

Key Points:

RIMOUSKI, Quebec, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the "Company" or "Puma") is pleased to outline its key accomplishments and discoveries in 2023 and present its proposed 2024 Exploration Program at its 100% owned Williams Brook Gold Project located in Northern New Brunswick.
Marcel Robillard, President and CEO of Puma, stated: “2023 was another extraordinary year for Puma.
Under its “DEAR” (Development, Exploration, Acquisition and Royalties) strategy, Puma continues to identify opportunities to increase shareholder value.
Puma raised $3,035,645 in May 2023 to fund 100% of its 2023 exploration program.

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on:

Monday, November 13, 2023

Under the agreement, SCYNEXIS has received the $90 million upfront payment as well as the first development milestone of $25 million.

Key Points:

Under the agreement, SCYNEXIS has received the $90 million upfront payment as well as the first development milestone of $25 million.
SCYNEXIS became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp.
Cash, cash equivalents and investments totaled $105.2 million on September 30, 2023, compared to $73.5 million on December 31, 2022.
Based upon the company’s current operating plan, SCYNEXIS believes that its existing cash, cash equivalents and investments provides a cash runway beyond two years.

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

Retrieved on:

Friday, December 8, 2023

Disease, Capsule, Immunodeficiency, Single-use medical devices, Safety, Food, Risk, Patient, Medical Mycology, FDA, Trial of the century, Pharmacokinetics, Azole, COVID-19, Bone marrow, TIMM, Pharmaceutical industry, IM, Astellas Pharma

NORTHBROOK, Ill., Dec. 8, 2023 /PRNewswire/ -- Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved CRESEMBA® (isavuconazonium sulfate), an azole antifungal drug, for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients. CRESEMBA for injection is approved for adults and now for pediatric patients 1 year of age and older. CRESEMBA capsules are approved for adults and now for pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater. With this approval, CRESEMBA is now the only azole antifungal therapy approved for the treatment of IA and IM in patients as young as one.

Key Points:

CRESEMBA for injection is approved for adults and now for pediatric patients 1 year of age and older.
CRESEMBA capsules are approved for adults and now for pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater.
With this approval, CRESEMBA is now the only azole antifungal therapy approved for the treatment of IA and IM in patients as young as one.
"IA, currently the most common invasive mold infection in these patients, and IM are associated with significant morbidity and high fatality rates.

Puma Exploration Samples 362 g/t Gold at Newly Optioned TIMM Gold Property

Retrieved on:

Wednesday, October 25, 2023

Lynx, JV, NSR, TSX Venture Exchange, Gold, TIMM, PUMA, Geology, News, Puma, Nature, Soil, Figure, Mining, Dome

The property is located only 10km east of St-Quentin, where Puma’s has its exploration office, comprises 223 claims covering 4,840 ha.

Key Points:

The property is located only 10km east of St-Quentin, where Puma’s has its exploration office, comprises 223 claims covering 4,840 ha.
He subsequently optioned it to different junior exploration companies over the years.
So far, the three (3) zones show a strike length of 625 m with samples varying from anomalous (0.1 g/t gold) up to 362 g/t gold.
To acquire a 70% interest in the TIMM property, PUMA will issue 250,000 shares to the vendor and complete $100K worth of work over two (2) years.

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Retrieved on:

Tuesday, October 24, 2023

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.

Key Points:

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.
“We are excited to see the progress in the development of this novel compound from the fungerp family,” said Dr. Martin Hoenigl, FECMM, Associate Professor of Translational Mycology at University of Graz, Austria and president of the European Confederation of Medical Mycology (ECMM).
Results illustrated the potent and broad-spectrum in vitro activity of SCY-247, including against a large array of yeasts, molds and dimorphic fungi.
Results also demonstrated SCY-247’s extensive tissue distribution in mice, including brain penetration.

F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim

Retrieved on:

Saturday, October 21, 2023

These findings were submitted as a late breaking abstract and exceptionally accepted for an oral presentation during the 11th Congress on Trends in Medical Mycology (TIMM) 2023 held in Athens, Greece, from 20-23 October 2023.

Key Points:

These findings were submitted as a late breaking abstract and exceptionally accepted for an oral presentation during the 11th Congress on Trends in Medical Mycology (TIMM) 2023 held in Athens, Greece, from 20-23 October 2023.
F2G and Shionogi & Co., Ltd. are collaborating to develop and commercialise olorofim, bringing the novel antifungal therapy to patients with invasive fungal infections.
F2G has commercial responsibility for olorofim in North America, and Shionogi has commercial responsibility for olorofim in Europe and Asia Pacific.
F2G and Shionogi are currently enrolling patients with invasive aspergillosis in a global Phase 3 study (OASIS) to compare treatment with olorofim versus AmBisome® followed by standard of care ( NCT05101187 ).

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece

Retrieved on:

Monday, October 16, 2023

Congress, Medical Mycology, Antimalarial medication, TIMM, EEST, Biotechnology, EDT, Pharmaceutical industry, Aspergillus

JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023.

Key Points:

JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023.
Title: SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against Broad-spectrum of Fungal Pathogens, and Dose-Dependent Tissue Distribution In Vivo
Time: 3:35 p.m EEST / 8:35 a.m. EDT

SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on:

Tuesday, March 29, 2022

Based on cash balance at December 31, 2021 and operating plan, SCYNEXIS has a projected cash runway into the second quarter of 2023.

Key Points:

Based on cash balance at December 31, 2021 and operating plan, SCYNEXIS has a projected cash runway into the second quarter of 2023.
BREXAFEMME delivered $0.6 million in net sales in fourth quarter 2021 and $1.1 million in total net sales in 2021.
Research and development expense for the fourth quarter of 2021 decreased to $7.7 million from $10.2 million versus the fourth quarter of 2020.
Selling, general& administrative (SG&A) expense for the fourth quarter of 2021 increased to $15.0 million from $5.2 million versus the fourth quarter of 2020.

Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Retrieved on:

Wednesday, November 10, 2021

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September30, 2021 and provided an update on its corporate activities and product pipeline.

Key Points:

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September30, 2021 and provided an update on its corporate activities and product pipeline.
We are pleased to report another highly productive quarter for Cidara, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
The gross proceeds to Cidara from these offerings, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $38.5 million.
Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.